Nerve growth factor Β polypeptide (NGFB) genetic variability: Association with the methadone dose required for effective maintenance treatment

Pharmacogenomics Journal

Volumn 12, Issue 4, 2012, Pages 319-327

  Levran, O ^a   Peles, E ^b   Hamon, S ^a   Randesi, M ^a   Zhao, C ^a   Zhang, B ^a   Adelson, M ^a,b   Kreek, M J ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

heroin addiction; methadone; nerve growth factor; NGFB; opioid addiction

Indexed keywords

METHADONE;

ABCB1 GENE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYP2B6 GENE; DRUG BLOOD LEVEL; DRUG METABOLISM; ETHNICITY; EXON; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HEROIN DEPENDENCE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; NGFB GENE; NUCLEOTIDE SEQUENCE; PHARMACODYNAMICS; PHARMACOGENETICS; PLESIOMORPHY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; METHADONE; MIDDLE AGED; NERVE GROWTH FACTOR; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84864352676     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.6     Document Type: Article

References (55)

1. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci 2000; 909: 186-216. (Pubitemid 30462040)
2. Kendler KS, Jacobson KC, Prescott CA, Neale MC. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry 2003; 160: 687-695. (Pubitemid 41079601)
3. Tsuang MT, Lyons MJ, Meyer JM, Doyle T, Eisen SA, Goldberg J et al. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 1998; 55: 967-972. (Pubitemid 28506837)
4. Tsuang MT, Lyons MJ, Eisen SA, Goldberg J, True W, Lin N et al. Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. Am J Med Genet 1996; 67: 473-477.
5. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005; 28: 321-329. (Pubitemid 40733141)
6. Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions. Nat Rev Drug Discov 2002; 1: 710-726. (Pubitemid 37361544)
7. Kreek MJ, Vocci FJ. History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat 2002; 23: 93-105. (Pubitemid 36151692)
8. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41: 89-295.
9. Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther 2008; 12: 109-124. (Pubitemid 351570866)
10. Chao MV, Rajagopal R, Lee FS. Neurotrophin signalling in health and disease. Clin Sci (Lond) 2006; 110: 167-173. (Pubitemid 43241478)
11. Carvalho AL, Caldeira MV, Santos SD, Duarte CB. Role of the brainderived neurotrophic factor at glutamatergic synapses. Br J Pharmacol 2008; 153(Suppl 1): S310-S324. (Pubitemid 351340985)
12. Bolanos CA, Nestler EJ. Neurotrophic mechanisms in drug addiction. Neuromolecular Med 2004; 5: 69-83. (Pubitemid 38391958)
13. Lang UE, Hellweg R, Kalus P, Bajbouj M, Lenzen KP, Sander T et al. Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology (Berl) 2005; 180: 95-99. (Pubitemid 40897075)
14. Uhl GR, Liu QR, Walther D, Hess J, Naiman D. Polysubstance abusevulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. Am J Hum Genet 2001; 69: 1290-1300. (Pubitemid 33124211)
15. Cheng CY, Hong CJ, Yu YW, Chen TJ, Wu HC, Tsai SJ. Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res Mol Brain Res 2005; 140: 86-90. (Pubitemid 41446150)
16. de Cid R, Fonseca F, Gratacos M, Gutierrez F, Martin-Santos R, Estivill X et al. BDNF variability in opioid addicts and response to methadone treatment: preliminary findings. Genes Brain Behav 2008; 7: 515-522. (Pubitemid 351991486)
17. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006; 311: 864-868. (Pubitemid 43228853)
18. Einarsdottir E, Carlsson A, Minde J, Toolanen G, Svensson O, Solders G et al. A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception. Hum Mol Genet 2004; 13: 799-805. (Pubitemid 38515209)
19. Larsson E, Kuma R, Norberg A, Minde J, Holmberg M. Nerve growth factor R221W responsible for insensitivity to pain is defectively processed and accumulates as proNGF. Neurobiol Dis 2009; 33: 221-228.
20. Fitzgibbon GJ, Kingston H, Needham M, Gaunt L. Haploinsufficiency of the nerve growth factor beta gene in a 1p13 deleted female child with an insensitivity to pain. Dev Med Child Neurol 2009; 51: 833-837.
21. Lang UE, Hellweg R, Bajbouj M, Gaus V, Sander T, Gallinat J. Gender-dependent association of a functional NGF polymorphism with anxiety-related personality traits. Pharmacopsychiatry 2008; 41: 196-199.
22. Akbarian S, Bates B, Liu RJ, Skirboll SL, Pejchal T, Coppola V et al. Neurotrophin-3 modulates noradrenergic neuron function and opiate withdrawal. Mol Psychiatry 2001; 6: 593-604. (Pubitemid 32772569)
23. Levran O, Londono D, O0Hara K, Nielsen DA, Peles E, Rotrosen J et al. Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav 2008; 7: 720-729.
24. Levran O, Londono D, O0Hara K, Randesi M, Rotrosen J, Casadonte P et al. Heroin addiction in African Americans: a hypothesis-driven association study. Genes Brain Behav 2009; 8: 531-540.
25. Adelson M, Peles E, Bodner G, Kreek MJ. Correlation between high methadone doses and methadone serum levels in methadone maintenance treatment (MMT) patients. J Addict Dis 2007; 26: 15-26. (Pubitemid 46797091)
26. Hodgkinson CA, Yuan Q, Xu K, Shen PH, Heinz E, Lobos EA et al. Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. Alcohol Alcohol 2008; 43: 505-515.
27. Enoch MA, Shen PH, Xu K, Hodgkinson C, Goldman D. Using ancestryinformative markers to define populations and detect population stratification. J Psychopharmacol 2006; 20: 19-26. (Pubitemid 44576654)
28. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155: 945-959. (Pubitemid 30397141)
29. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265. (Pubitemid 40202029)
30. Levran O, O0Hara K, Peles E, Li D, Barral S, Ray B et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 2008; 17: 2219-2227. (Pubitemid 351916578)
31. McClung CA, Nestler EJ. Neuroplasticity mediated by altered gene expression. Neuropsychopharmacology 2008; 33: 3-17. (Pubitemid 350191310)
32. Fahnestock M, Michalski B, Xu B, Coughlin MD. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer0s disease. Mol Cell Neurosci 2001; 18: 210-220. (Pubitemid 32846529)
33. Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 2006; 29: 507-538. (Pubitemid 44476854)
34. Fiore M, Chaldakov GN, Aloe L. Nerve growth factor as a signaling molecule for nerve cells and also for the neuroendocrine-immune systems. Rev Neurosci 2009; 20: 133-145.
35. Bie B, Zhang Z, Cai YQ, Zhu W, Zhang Y, Dai J et al. Nerve growth factor-regulated emergence of functional delta-opioid receptors. J Neurosci 2010; 30: 5617-5628.
36. Narita M, Kuzumaki N, Miyatake M, Sato F, Wachi H, Seyama Y et al. Role of delta-opioid receptor function in neurogenesis and neuroprotection. J Neurochem 2006; 97: 1494-1505. (Pubitemid 43725587)
37. Kieffer BL, Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol 2002; 66: 285-306. (Pubitemid 34518287)
38. Chen YL, Monteith N, Law PY, Loh HH. Dynamic association of p300 with the promoter of the G protein-coupled rat delta opioid receptor gene during NGF-induced neuronal differentiation. Biochem Biophys Res Commun 2010; 396: 294-298.
39. Chen YL, Law PY, Loh HH. Action of NF-kappaB on the delta opioid receptor gene promoter. Biochem Biophys Res Commun 2007; 352: 818-822. (Pubitemid 44880328)
40. Wu VW, Mo Q, Yabe T, Schwartz JP, Robinson SE. Perinatal opioids reduce striatal nerve growth factor content in rat striatum. Eur J Pharmacol 2001; 414: 211-214. (Pubitemid 32181888)
41. Yoon SJ, Roh S, Lee H, Lee JY, Lee BH, Kim YK et al. Possible role of nerve growth factor in the pathogenesis of alcohol dependence. Alcohol Clin Exp Res 2006; 30: 1060-1065. (Pubitemid 43823269)
42. Doehring A, Hentig N, Graff J, Salamat S, Schmidt M, Geisslinger G et al. Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet Genomics 2009; 19: 407-414.
43. Crettol S, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1722-1727.
44. Lawford BR, Young RM, Noble EP, Sargent J, Rowell J, Shadforth S et al. The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet 2000; 96: 592-598.
45. Lotsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmoller J et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 2006; 79: 72-89. (Pubitemid 43069580)
46. Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80: 668-681. (Pubitemid 44920225)
47. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 2006; 80: 682-690. (Pubitemid 44920224)
48. Fonseca F, Gratacos M, Escaramis G, De Cid R, Martin-Santos R, Fernandez-Espejo E et al. Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. Mol Diagn Ther 2010; 14: 171-178.
49. Barratt DT, Coller JK, Somogyi AA. Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 323-331. (Pubitemid 43872882)
50. Lotsch J, Pruss H, Veh RW, Doehring A. A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size. Pharmacogenet Genomics 2010; 20: 291-297.
51. Mercader JM, Saus E, Aguera Z, Bayes M, Boni C, Carreras A et al. Association of NTRK3 and its interaction with NGF suggest an altered cross-regulation of the neurotrophin signaling pathway in eating disorders. Hum Mol Genet 2008; 17: 1234-1244. (Pubitemid 351566960)
52. Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP 3A and P glycoprotein activities. Clin Pharmacol Ther 2008; 84: 506-512.
53. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010; 19: 4-16.
54. Need AC, Kasperaviciute D, Cirulli ET, Goldstein DB. A genome-wide genetic signature of Jewish ancestry perfectly separates individuals with and without full Jewish ancestry in a large random sample of European Americans. Genome Biol 2009; 10: R7.
55. Behar DM, Yunusbayev B, Metspalu M, Metspalu E, Rosset S, Parik J et al. The genome-wide structure of the Jewish people. Nature 2010; 466: 238-242.